Pradžia › Skydliaukės vėžys › Texas
Skydliaukės vėžys klinikiniai tyrimai Texas
15 tyrimai dėl Skydliaukės vėžys ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, Dallas
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07124000Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
- MD Anderson Cancer Center, Houston
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT06507878Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT05786924Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT07218315Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT06959511Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 2 iki 25 · Visoms lytims · Atnaujinta 2026-07-24 · NCT06458036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-05-27 · NCT03093116An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
- M D Anderson Cancer Center, Houston
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-22 · NCT04589624Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-06 · NCT06239194Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-15 · NCT04693377cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 40 ir vyresni · Visoms lytims · Atnaujinta 2026-01-20 · NCT05366881Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 2 iki 99 · Visoms lytims · Atnaujinta 2025-11-14 · NCT05783323Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
- University of Texas Health Science Center, San Antonio
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-15 · NCT03160274Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2024-12-12 · NCT05668962Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.